An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment

A redox-responsive supramolecular nanocarrier was constructed from the self-assembly of spermine modified cyclodextrin and oxaliplatin prodrug. The nanocarrier could preferentially accumulate in polyamine transporter over-expressing HCT116 cells, releasing drugs under a reducing intracellular enviro...

Full description

Saved in:
Bibliographic Details
Main Authors: Lim, Wei Qi, Phua, Fiona Soo Zeng, Chen, Hongzhong, Zhao, Yanli
Other Authors: School of Physical and Mathematical Sciences
Format: Article
Language:English
Published: 2020
Subjects:
Online Access:https://hdl.handle.net/10356/137605
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-137605
record_format dspace
spelling sg-ntu-dr.10356-1376052023-02-28T19:46:03Z An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment Lim, Wei Qi Phua, Fiona Soo Zeng Chen, Hongzhong Zhao, Yanli School of Physical and Mathematical Sciences Science::Chemistry Nanomedicine Nanocarrier A redox-responsive supramolecular nanocarrier was constructed from the self-assembly of spermine modified cyclodextrin and oxaliplatin prodrug. The nanocarrier could preferentially accumulate in polyamine transporter over-expressing HCT116 cells, releasing drugs under a reducing intracellular environment to maximize anticancer treatment. NRF (Natl Research Foundation, S’pore) MOE (Min. of Education, S’pore) Accepted version 2020-04-06T04:57:57Z 2020-04-06T04:57:57Z 2018 Journal Article Lim, W. Q., Phua, F. S. Z., Chen, H., & Zhao, Y. (2018). An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment. Chemical Communications, 54, 12762-12765. doi:10.1039/c8cc07858k 1359-7345 https://hdl.handle.net/10356/137605 10.1039/c8cc07858k 54 12762 12765 en Chemical Communications © 2018 The Author(s) (Royal Society of Chemistry). All rights reserved. This paper was published in Chemical Communications and is made available with permission of The Author(s) (Royal Society of Chemistry). application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Chemistry
Nanomedicine
Nanocarrier
spellingShingle Science::Chemistry
Nanomedicine
Nanocarrier
Lim, Wei Qi
Phua, Fiona Soo Zeng
Chen, Hongzhong
Zhao, Yanli
An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
description A redox-responsive supramolecular nanocarrier was constructed from the self-assembly of spermine modified cyclodextrin and oxaliplatin prodrug. The nanocarrier could preferentially accumulate in polyamine transporter over-expressing HCT116 cells, releasing drugs under a reducing intracellular environment to maximize anticancer treatment.
author2 School of Physical and Mathematical Sciences
author_facet School of Physical and Mathematical Sciences
Lim, Wei Qi
Phua, Fiona Soo Zeng
Chen, Hongzhong
Zhao, Yanli
format Article
author Lim, Wei Qi
Phua, Fiona Soo Zeng
Chen, Hongzhong
Zhao, Yanli
author_sort Lim, Wei Qi
title An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
title_short An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
title_full An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
title_fullStr An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
title_full_unstemmed An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
title_sort oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment
publishDate 2020
url https://hdl.handle.net/10356/137605
_version_ 1759854973709975552